Diabetes

In addition to improved efficacy, newer generations of anti-obesity medications have significantly improved safety concerns.

Expert Jennifer Clements discussed the evolving landscape of weight management medications, clinical considerations, and obstacles to use.

The oral medication activates an “anti-hunger” molecule which may prevent people from overeating.

Raj Gupta, DC, discusses holistic approaches to managing type 2 diabetes without medication by addressing root causes like diet, toxins, and stress.

A notable revision now includes a dual GIP and GLP-1 receptor agonist (tirzepatide) as an additional option for glycemic management, preferred over insulin.

This podcast episode discussed the impact of celebrity endorsements on trends in weight loss drugs like Ozempic, body image issues, and the role of pharmacists in educating patients on appropriate use of GLP-1 medications for weight management and chronic diseases.

GBS can cause transcriptional adaptations, which may increase risk of poor neonate outcomes.

CGM enhances diabetes management in pregnancy, improving outcomes.

Teplizumab is indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and pediatric patients 8 years of age and older with stage 2 T1D.

Promising data have emerged suggesting a significant weight loss benefit for patients using GLP-1 agonists and GLP-1/GIP dual agonists.

Continuous glucose monitoring (CGM) is a valuable tool in managing diabetes, offering real-time data on glucose levels throughout the day.

Diabetes is a known risk factor for cognitive decline and small vessel disease.

Vitamin D preserved insulin-producing cells and cell function, which can reduce complications in young patients.

The continuous glucose monitoring system will be available for purchase online and without a prescription starting in summer 2024.

In the study, investigators found superior kidney outcomes with injectable semaglutide (Ozempic) for individuals with type 2 diabetes and chronic kidney disease.

In some instances, metabolites can predict risk in patients who still have normal glucose biomarkers.

Nearly 60% of patients who regained all the weight stayed in remission at 5 years post-surgery, according to study results.

Continued doses of denosumab reduced the incidence of diabetes by more than 1000 patients compared to an initial dose alone.

In a projective model, tirzepatide saved patients more than $15,000 per quality-adjusted life-year.

This accreditation allows pharmacists to give diabetes education to patients with Medicare and receive Medicare reimbursement.

Mouthwash that contains chlorhexidine gluconate was especially effective at improving hyperglycemic status in younger patients with diabetes.

Diabetes self-management education works with patients own goals to manage the condition, prevent cardiovascular risk, and stay safe.

This agent can prevent the depletion of heparan sulphate in the endothelial glycocalyx layer of endothelial cells, ultimately protecting against vision loss and renal failure caused by diabetes.

Providing continuity of care with the involvement of midwives also appeared to reduce inequities in care for multi-ethnic patients.

By involving pharmacists, patients can see improved medication adherence, improved outcomes, and, as a result, reduced health care costs